Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker DNLI
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Chin Peter Scott Officer | DNLI Denali Therapeutics Inc. | 1,654 | $36.9K | — | Sep 4, 2026 | Form 4 ↗ 5 days later · 1,654 shares | Form 144 ↗ |
| Sep 2, 2026 | Nancy Thornberry Director | DNLI Denali Therapeutics Inc. | 11,439 | $266.1K | 10b5-1 | Sep 2, 2026 | Form 4 ↗ 2 days later · 11,439 shares | Form 144 ↗ |
| Sep 1, 2026 | Alexander Schuth Officer | DNLI Denali Therapeutics Inc. | 2,768 | $65.8K | 10b5-1 | Sep 1, 2026 | Form 4 ↗ 2 days later · 2,768 shares | Form 144 ↗ |
| Aug 11, 2026 | Alexander O. Schuth Officer | DNLI Denali Therapeutics Inc. | 2,857 | $71.6K | — | Aug 11, 2026 | Form 4 ↗ 2 days later · 2,857 shares | Form 144 ↗ |
| Feb 5, 2026 | Carole Ho Former Affiliate | DNLI Denali Therapeutics Inc. | 39,490 | $801.4K | — | Feb 5, 2026 | — | Form 144 ↗ |
| Feb 4, 2026 | Carole Ho Former Affiliate | DNLI Denali Therapeutics Inc. | 150,000 | $3.2M | — | Feb 4, 2026 | — | Form 144 ↗ |
| Feb 3, 2026 | Carole Ho Former Affiliate | DNLI Denali Therapeutics Inc. | 150,000 | $3.3M | — | Feb 3, 2026 | — | Form 144 ↗ |
| Jan 6, 2026 | Ho Carole Consultant | DNLI Denali Therapeutics Inc. | 17,218 | $284.1K | — | Jan 6, 2026 | — | Form 144 ↗ |
| Jan 6, 2026 | Alexander O. Schuth Officer | DNLI Denali Therapeutics Inc. | 17,218 | $284.1K | — | Jan 6, 2026 | Form 4 ↗ 2 days later · 17,218 shares | Form 144 ↗ |
| Jan 6, 2026 | Ryan J. Watts Director, Officer | DNLI Denali Therapeutics Inc. | 35,198 | $580.8K | — | Jan 6, 2026 | Form 4 ↗ 2 days later · 35,198 shares | Form 144 ↗ |
| Dec 4, 2025 | Carole Ho Officer | DNLI Denali Therapeutics Inc. | 1,882 | $35.8K | 10b5-1 | Dec 4, 2025 | — | Form 144 ↗ |
| Aug 13, 2025 | Carole Ho Officer | DNLI Denali Therapeutics Inc. | 806 | $10.7K | 10b5-1 | Aug 13, 2025 | Form 4 ↗ 1 day later · 3,743 shares | Form 144 ↗ |
| Aug 12, 2025 | Alexander O. Schuth Officer | DNLI Denali Therapeutics Inc. | 2,937 | $39.9K | — | Aug 12, 2025 | Form 4 ↗ 2 days later · 2,937 shares | Form 144 ↗ |
| Aug 12, 2025 | Ho Carole Officer | DNLI Denali Therapeutics Inc. | 2,937 | $39.9K | — | Aug 12, 2025 | Form 4 ↗ 2 days later · 3,743 shares | Form 144 ↗ |
| Jul 9, 2025 | Ryan J. Watts Officer | DNLI Denali Therapeutics Inc. | 495,282 | $7.1M | 10b5-1 | Jul 9, 2025 | Form 4 ↗ 2 days later · 495,282 shares | Form 144 ↗ |
| Jan 7, 2025 | Ho Carole Officer | DNLI Denali Therapeutics Inc. | 2,907 | $60.5K | — | Jan 7, 2025 | Form 4 ↗ 1 day later · 15,162 shares | Form 144 ↗ |
| Jan 7, 2025 | Alexander O. Schuth Officer | DNLI Denali Therapeutics Inc. | 2,907 | $60.5K | — | Jan 7, 2025 | Form 4 ↗ 1 day later · 15,162 shares | Form 144 ↗ |
| Jan 7, 2025 | Ryan J. Watts Director, Officer | DNLI Denali Therapeutics Inc. | 7,650 | $159.2K | — | Jan 7, 2025 | Form 4 ↗ 1 day later · 36,916 shares | Form 144 ↗ |
| Jan 7, 2025 | Steve E. Krognes Director | DNLI Denali Therapeutics Inc. | 3,339 | $69.5K | — | Jan 7, 2025 | Form 4 ↗ 1 day later · 3,339 shares | Form 144 ↗ |
| Jan 7, 2025 | Alexander O. Schuth Officer | DNLI Denali Therapeutics Inc. | 12,255 | $247.8K | — | Jan 6, 2025 | Form 4 ↗ 1 day later · 15,162 shares | Form 144 ↗ |
| Jan 7, 2025 | Ryan J. Watts Director, Officer | DNLI Denali Therapeutics Inc. | 29,266 | $591.7K | — | Jan 6, 2025 | Form 4 ↗ 1 day later · 36,916 shares | Form 144 ↗ |
| Jan 7, 2025 | Ho Carole Officer | DNLI Denali Therapeutics Inc. | 12,255 | $247.8K | — | Jan 6, 2025 | Form 4 ↗ 1 day later · 15,162 shares | Form 144 ↗ |
| Jan 2, 2025 | Vicki Lee Sato Director | DNLI Denali Therapeutics Inc. | 6,160 | $125.5K | 10b5-1 | Jan 2, 2025 | Form 4 ↗ 1 day later · 3,080 shares | Form 144 ↗ |
| Dec 31, 2024 | Steve Krognes Director | DNLI Denali Therapeutics Inc. | 30,000 | $607.2K | 10b5-1 | Dec 31, 2024 | Form 4 ↗ 3 days later · 30,000 shares | Form 144 ↗ |
| Nov 12, 2024 | David Schenkein Director | DNLI Denali Therapeutics Inc. | 59,441 | $1.9M | 10b5-1 | Nov 11, 2024 | Form 4 ↗ 1 day later · 59,441 shares | Form 144 ↗ |
| Nov 7, 2024 | Alexander Schuth Officer | DNLI Denali Therapeutics Inc. | 15,558 | $459.7K | 10b5-1 | Nov 7, 2024 | Form 4 ↗ 5 days later · 15,558 shares | Form 144 ↗ |
| Oct 18, 2024 | Ryan Watts Director, Officer | DNLI Denali Therapeutics Inc. | 40,000 | $1.1M | 10b5-1 | Oct 18, 2024 | Form 4 ↗ 4 days later · 40,000 shares | Form 144 ↗ |
| Sep 30, 2024 | Steve Krognes Director | DNLI Denali Therapeutics Inc. | 30,000 | $882.9K | 10b5-1 | Sep 30, 2024 | Form 4 ↗ 2 days later · 30,000 shares | Form 144 ↗ |
| Sep 13, 2024 | Vicki Lee Sato Director | DNLI Denali Therapeutics Inc. | 6,160 | $172.2K | 10b5-1 | Sep 13, 2024 | Form 4 ↗ 53 days later · 3,080 shares | Form 144 ↗ |
| Aug 21, 2024 | Carole Ho Officer | DNLI Denali Therapeutics Inc. | 20,005 | $473.1K | 10b5-1 | Aug 21, 2024 | — | Form 144 ↗ |
| Aug 21, 2024 | Alexander Schuth Officer | DNLI Denali Therapeutics Inc. | 2,547 | $60.2K | 10b5-1 | Aug 21, 2024 | Form 4 ↗ 83 days later · 15,558 shares | Form 144 ↗ |
| Aug 20, 2024 | Alexander Schuth Officer | DNLI Denali Therapeutics Inc. | 3,353 | $80.3K | 10b5-1 | Aug 20, 2024 | Form 4 ↗ 84 days later · 15,558 shares | Form 144 ↗ |
| Aug 20, 2024 | Steve E. Krognes Director | DNLI Denali Therapeutics Inc. | 1,727 | $41.1K | — | Aug 20, 2024 | Form 4 ↗ 43 days later · 30,000 shares | Form 144 ↗ |
| Aug 20, 2024 | Alexander O. Schuth Officer | DNLI Denali Therapeutics Inc. | 2,453 | $58.4K | — | Aug 20, 2024 | Form 4 ↗ 84 days later · 15,558 shares | Form 144 ↗ |
| Aug 20, 2024 | Ryan J. Watts Director, Officer | DNLI Denali Therapeutics Inc. | 2,260 | $53.8K | — | Aug 20, 2024 | Form 4 ↗ 63 days later · 40,000 shares | Form 144 ↗ |
| Aug 20, 2024 | Ho Carole Officer | DNLI Denali Therapeutics Inc. | 2,453 | $58.4K | — | Aug 20, 2024 | — | Form 144 ↗ |
| Aug 13, 2024 | Alexander O. Schuth Officer | DNLI Denali Therapeutics Inc. | 2,272 | $52.0K | — | Aug 13, 2024 | Form 4 ↗ 91 days later · 15,558 shares | Form 144 ↗ |
| Aug 13, 2024 | Ho Carole Officer | DNLI Denali Therapeutics Inc. | 2,337 | $53.5K | — | Aug 13, 2024 | — | Form 144 ↗ |
| Jul 1, 2024 | Vicki Lee Sato Director | DNLI Denali Therapeutics Inc. | 6,160 | $143.0K | 10b5-1 | Jul 1, 2024 | — | Form 144 ↗ |
| Jul 1, 2024 | Steve Krognes Director | DNLI Denali Therapeutics Inc. | 30,000 | $696.6K | 10b5-1 | Jul 1, 2024 | — | Form 144 ↗ |
| Jun 6, 2024 | Jennifer Cook Director | DNLI Denali Therapeutics Inc. | 1,458 | $31.9K | 10b5-1 | Jun 6, 2024 | — | Form 144 ↗ |
| Apr 15, 2024 | Vicki Lee Sato Director | DNLI Denali Therapeutics Inc. | 3,340 | $61.0K | 10b5-1 | Apr 15, 2024 | — | Form 144 ↗ |
| Apr 1, 2024 | Steve Edward Krognes Director | DNLI Denali Therapeutics Inc. | 92,500 | $1.9M | 10b5-1 | Apr 1, 2024 | — | Form 144 ↗ |
| Feb 14, 2024 | Alexander Schuth Officer | DNLI Denali Therapeutics Inc. | 20,128 | $343.4K | 10b5-1 | Feb 14, 2024 | — | Form 144 ↗ |
| Feb 14, 2024 | Ho Carole Officer | DNLI Denali Therapeutics Inc. | 1,405 | $24.0K | 10b5-1 | Feb 14, 2024 | — | Form 144 ↗ |
| Feb 13, 2024 | Steve E. Krognes Director | DNLI Denali Therapeutics Inc. | 2,750 | $47.5K | — | Feb 13, 2024 | — | Form 144 ↗ |
| Feb 13, 2024 | Ho Carole Officer | DNLI Denali Therapeutics Inc. | 2,784 | $48.1K | — | Feb 13, 2024 | — | Form 144 ↗ |
| Feb 13, 2024 | Alexander O. Schuth Officer | DNLI Denali Therapeutics Inc. | 2,716 | $47.0K | — | Feb 13, 2024 | — | Form 144 ↗ |
| Feb 13, 2024 | Ryan J. Watts Director, Officer | DNLI Denali Therapeutics Inc. | 9,589 | $165.8K | — | Feb 13, 2024 | — | Form 144 ↗ |
| Jan 16, 2024 | Vicki Lee Sato Director | DNLI Denali Therapeutics Inc. | 4,998 | $92.7K | 10b5-1 | Jan 16, 2024 | — | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 7:12 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances